Moti L. Kashyap

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events

Sander J. Robins, Dorothea Collins, Janet Wittes et al. · JAMA · 2001 · 922 citations

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Interchange of Apolipoproteins between Chylomicrons and High Density Lipoproteins during Alimentary Lipemia in Man

Richard J. Havel, John P. Kane, Moti L. Kashyap · Journal of Clinical Investigation · 1973 · 528 citations · Full text

Obesity, Metabolic Syndrome, Nutrition +15

Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes

John J. Albers, April Slee, Kevin D. O’Brien et al. · Journal of the American College of Cardiology · 2013 · 309 citations · Full text

Metabolic Syndrome, Vascular Disease, Apolipoproteins A-1 +12